Therapeutic Areas
Oncology
In some cancers, tumor-driven or pathological angiogenesis induces the development of new blood vessels to the tumor through an increase in the production of vascular endothelial growth factor or VEGF. Over-expression of VEGF plays a key role in multiple diseases including cancer and macular degeneration.
At PTC, we are committed to finding treatment options for patients living with serious, life-threatening diseases. PTC299, an investigational new drug, is an oral small molecule inhibitor of VEGF production with selectivity for pathological VEGF without affecting physiological VEGF. PTC299 has a unique mechanism of action that is being evaluated in a variety of tumor types in multiple clinical trials.